Bio Behavioral Health

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Depression14 trials
• Alzheimer disease7 trials
• Bipolar disorder1 trial
• Migraine1 trial
• Schizophrenia1 trial

Phase

• Phase 314 trials
• Phase 28 trials

Status

• Completed7 trials
• Active, not recruiting6 trials
• Recruiting6 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Intra-Cellular Therapies, Inc.3 trials
• Otsuka Pharmaceutical Development & Commercialization, Inc.3 trials
• Xenon Pharmaceuticals Inc.3 trials
• Biohaven Therapeutics Ltd.2 trials
• COMPASS Pathways2 trials
• and 7 more

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Eli Lilly and Company· Source

  Contact: Ashok Patel (principal investigator)

• Recruiting

  A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07816367· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Ashok Patel

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Cybin IRL Limited· Source

  Contact: Jessica Sutton

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Cybin IRL Limited· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Bristol-Myers Squibb· Source

  Contact: Ashok Patel, Site 2650

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  NCT07076407· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression4 recruiting
• Alzheimer disease3 recruiting
• Migraine1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Completed

  A Study to Test Different Doses of BI 1569912 in People With Depression

  NCT06558344· Phase 2· Boehringer Ingelheim· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· COMPASS Pathways· Source

• Completed

  Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

  NCT05536414· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT03393520· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source